Evolution of the Cancer Stem Cell Model

TL;DR: This paper considers several aspects of current methodologies for drug discovery of antibacterial and antifungals, anti-tropical diseases, antibiofilm and antiquorum sensing, anticancer and neuroprotectors, and a comprehensive overview on recent advances that will foster the pharmaceutical industry.

TL;DR: It is shown here that RBP4 and STRA6 expression is associated with poor oncologic prognosis and that this pathway is an important link through which consumption of HFD contributes to colon carcinogenesis.

TL;DR: The key strengths, weaknesses, and potential applications of cell- and animal-based models of GBM are presented, highlighting the experience with the glioblastoma stem-like patient cell-derived xenograft model and its utility in drug discovery.

TL;DR: The ability to prospectively identify tumorigenic cancer cells will facilitate the elucidation of pathways that regulate their growth and survival and strategies designed to target this population may lead to more effective therapies.

TL;DR: It is shown that hypermutation localized to small genomic regions, ‘kataegis’, is found in many cancer types, and this results reveal the diversity of mutational processes underlying the development of cancer.

TL;DR: It is reported that the induction of an EMT in immortalized human mammary epithelial cells (HMLEs) results in the acquisition of mesenchymal traits and in the expression of stem-cell markers, and it is shown that those cells have an increased ability to form mammospheres, a property associated with mammARY epithelial stem cells.